Almudena Burillo, M.D., Ph.D.

Thornton and Wells reviewed 131 ovarian enlargements in pregnancy antiviral neuraminidase inhibitor buy 200mg paxlovid free shipping, 81 of which were removed (including 1 carcinoma and 6 borderline lesions) hiv infection rates nigeria discount 200 mg paxlovid overnight delivery. Thirty-nine were greater than 5 cm in diameter and had simple internal echo patterns and smooth walls; 3 of these were borderline malignant neoplasms hiv infection mosquito bite buy cheap paxlovid. Hoffman reviewed 13 reports of ovarian neoplasms removed in pregnancy and found benign cystadenomas or cystic teratomas most frequently diagnosed hiv infection rates us discount 200 mg paxlovid amex. The Hoffman review also included a summary of 127 malignant ovarian lesions found during pregnancy xl3 accion antiviral buy generic paxlovid. A recent literature review by Kwon and colleagues describing the various histologies of ovarian tumors found in pregnancy appears in Table 15-7. Borderline and frankly malignant epithelial lesions were the most commonly encountered during pregnancy. Borderline Ovarian Tumors Adnexal masses greater than 6 cm that persist into the second trimester warrant removal at approximately 18 weeks of gestational age. Among epithelial tumors, serous carcinoma and serous tumors of low malignant potential are readily encountered. Intervention before the second trimester is not advisable because this does not give time for the ovarian mass to resolve on its own and could compromise ovarian hormone production before the placenta is fully functional. The table should be tilted to the left or the right with the patient supine to move the uterus away from the site of trocal insertion. The left upper quadrant or subxyphoid insertion of the trocar should be used with at least 6 cm between the point of entry and the top of the fundus. The open Hasson technique is preferred over the Veress technique, although both have been used successfully in pregnancy. Ultrasound guidance may be used with the Veress technique together with elevation of the abdominal wall to reduce the risk of uterine injury. Intra-abdominal pressure should be kept below 15 mm Hg with the patient in Trendelenburg position to ensure adequate venous return and uteroplacental blood flow during the operation. Depending on the circumstances and gestational age, fetal monitoring may be advisable. All 33 patients for whom follow-up data were available were found to be alive without disease (range 1 year to 20 years and 5 months). Recent evidence suggests that the hormonal influence of pregnancy can effect histologic changes in serous low malignant potential tumors that, if not sorted out and characterized appropriately, could be mistaken for frankly invasive carcinoma. Although these lesions remained within the spectrum of low malignant potential tumors, the histologic features were worrisome for a more aggressive clinical course, yet all 10 patients remained disease free following a variety of treatment modalities. We advise prompt recognition of these histologic findings following cystectomy and/or oophorectomy during pregnancy so as to classify them accordingly as being borderline rather than to confuse them with low-grade serous papillary carcinomas. Of additional interest is that in two cases the tumor was resected both during pregnancy and after parturition (2 months and 3 years), and there was significant regression of the epithelial proliferation, the number of eosinophilic cells, and the amount of mucin production the second time around; this regression following parturition supports a hormonal etiology of these unusual histologic features. In contrast to frankly malignant ovarian carcinomas, unilateral adnexectomy is all that is required during pregnancy for the serous low malignant potential tumor. Frankly Malignant Ovarian Tumors Malignant ovarian tumors account for only 2% to 5% of all ovarian neoplasms found in pregnancy. The diagnosis is usually fortuitous in that the patient undergoes laparotomy for an adnexal mass that is subsequently found to be malignant. In many instances, the close observation of the pregnant patient has led to the discovery of a lesion in the earlier stages. These include not only malignant germ cell tumors and sex cord­stromal cell cancers, but also some epithelial malignancies. The contralateral ovary should be carefully inspected and biopsied if anything suspicious is detected. In the scenario of a clinical stage I ovarian carcinoma, unilateral adnexectomy, omentectomy, unilateral pelvic and aortocaval lymph node sampling, peritoneal biopsies, and fourquadrant washings can be safely carried out during pregnancy, with chemotherapy reserved for those patients who are upstaged on histopathologic analysis. Although a considerable number of these cancers present with early-stage disease (in both pregnant and nonpregnant patients), there are several reports of advanced cancers associated with pregnancy. Combination chemotherapy during pregnancy has been given without deleterious effects on the fetus. All other histologic types require adjuvant chemotherapy, and therefore unilateral adnexectomy is all that is typically accomplished at the time of laparotomy, along with removal of all gross metastatic disease. Because most malignant germ cell tumors will be unilateral (the dysgerminoma is the exception in 10% of cases), it is inappropriate to remove both ovaries. Even when the opposite side may harbor an occult dysgerminoma, it is often not necessary to remove the entire contralateral ovary. If, however, both ovaries are grossly involved by malignancy and the pregnancy is in the second trimester and thus free from hormonal support by the corpus luteum, both ovaries should be extracted. Chemotherapy regimens currently used for this disease comprise bleomycin, etoposide, and cisplatin. Combined chemotherapy has improved survival markedly for malignant germ cell ovarian tumors and can permit preservation of childbearing capacity and maintenance of the existing pregnancy if the disease is stage I. If the diagnosis is made during the first or second trimester, the patient must decide whether to permit the pregnancy to continue to viability before adjuvant chemotherapy is instituted. Because these tumors characteristically grow rapidly and often recur within months when therapy is withheld, delays in initiating systemic therapy can be harmful. Indeed, the high success rate obtained with adjuvant chemotherapy has been recorded with use of this modality in the immediate postoperative period. The effect of a treatment-free interval of several months before the commencement of adjuvant chemotherapy has not been tested adequately. Thus the patient with a malignant ovarian germ cell tumor discovered early in pregnancy and in need of chemotherapy is faced with a dilemma for which no data are available. Malone and colleagues described a patient with stage Ic endodermal sinus tumor diagnosed in the 25th week of gestation who received two cycles of combination chemotherapy consisting of vinblastine, bleomycin, and cisplatin and delivered a healthy boy by cesarean section at 32 weeks of gestation. To our knowledge, this was the first report of a case of a patient who had endodermal sinus tumor treated with combination chemotherapy during pregnancy that apparently had a successful outcome for both mother and infant. Therapeutic decisions for patients who have more advanced stages of these tumors are also difficult and controversial. As in earlier stages, the uterus and opposite ovary can be preserved if metastatic tumor is not found in these locations. Some clinicians preserve the uterus and opposite ovary under all conditions in the hope that postoperative chemotherapy will sterilize those organs also. Delays in withholding chemotherapy are not warranted, and uterine evacuation is often requested because of fear of potential teratogenic effects when chemotherapy is required during the first trimester. The subject of adjuvant chemotherapy in pregnancy is discussed later, but we emphasize that all chemotherapeutic agents are theoretically teratogenic. Although retrospective studies have not shown frequent congenital abnormalities in patients treated in the second and third trimesters, many newer agents have not been used frequently in pregnancy. Optimal staging should include a pelvic and periaortic lymphadenectomy on the side of the tumor mass because dysgerminomas metastasize primarily through the lymphatic system to the ipsilateral pelvic and periaortic lymph nodes. A mass on scan or a suspicious lymph node on lymphangiography should be evaluated at re-exploration. Emergency surgical intervention and obstetric complications are common in patients with dysgerminomas. Karlen and associates reviewed 27 cases of dysgerminoma associated with pregnancy. Torsion and incarceration were found commonly in this group of patients who had rapidly enlarging neoplasms averaging 25 cm in diameter. Obstetric complications occurred in nearly half the patients, and fetal demise occurred in one quarter of the reviewed cases. There were recurrences in 30% of 23 stage Ia tumors treated by unilateral oophorectomy, which calls into question the philosophy of treating these patients conservatively. The extent of exploration was not known in most cases, however, and therefore accuracy of staging cannot be assessed. In our experience, lesions that are confined to one ovary have a 10% recurrence rate. Although most of these lesions recur in the first 2 years after surgery, we believe that this group of patients can continue their pregnancy safely with completion of their proper evaluation in the puerperium. Sex Cord­Stromal Tumors in Pregnancy Granulosa and Sertoli­Leydig cell tumors together account for only 2% to 3% of all ovarian neoplasms. Although granulosa cell tumors are most commonly discovered in perimenopausal or postmenopausal women, 10% to 20% are encountered during the reproductive years. Sertoli­Leydig cell tumors occur in women in the reproductive age group in 74% of cases. It is critical that these entities are distinguished from ovarian decidualization, luteoma of pregnancy, or even benign granulosa cell proliferations observed with pregnancy. Thus, because their biologic behavior is akin to that of neoplasms of low malignant potential, it is recommended that they be managed conservatively. Young and colleagues reported a series of 17 granulosa cell, 13 Sertoli­Leydig cell, and 6 unclassified sex cord­stromal tumors diagnosed during pregnancy or the puerperium. Eleven patients had abdominal pain or swelling when they were first seen by a physician, 5 were in shock, 2 had virilization, and 1 had vaginal bleeding. Three asymptomatic patients underwent exploration because of palpable masses, and one underwent exploration because of an adnexal mass found on ultrasound examination. In 13 patients, the tumors were discovered during cesarean sections; 5 patients had dystocia, and the tumors were incidental findings in 8 patients. Young and colleagues uncovered four major sources of difficulty in the interpretation of their series of 36 cases: 1. Pregnancy-induced changes in other neoplastic and non-neoplastic lesions of the ovary that cause them to simulate sex cord­stromal tumors both morphologically and in terms of endocrine function Indeed, the pregnancy-associated tumors commonly exhibited alterations related to the pregnant state that tended to obscure characteristics and familiar features that are apparent in tumors removed from nonpregnant patients. The most striking changes included intercellular edema and increased extent of luteinization in the granulosa cell tumors and of Leydig cell maturation in the Sertoli­Leydig cell tumors. It is important to note that the edema often blurred the architectural patterns of the tumors and distorted the cytologic features of the neoplastic cells. The marked luteinization and Leydig cell maturation interfered with the recognition of these cells. The end result was that these pregnancy-associated changes made identification of the tumor type more difficult. Granulosa cell tumors are clinically estrogenic in approximately two thirds of cases, and Sertoli­Leydig cell tumors are virilizing in nearly 50% of cases. These hormonal manifestations often suggest the correct diagnosis to the gynecologist. It is quite probable, however, that many of these tumors were secreting estrogens in large quantities. Furthermore, only 16% (n = 5) of the 36 sex cord­stromal tumors were associated with clinical evidence of excess androgens (virilization in 4 cases, and hirsutism in only 1 case). In fact, one of the masculinizing tumors was the largest in their series (32 cm in maximal diameter) and may have been secreting androgens in such great abundance that the aromatizing capacity of the placenta was exceeded. Several other types of ovarian neoplasms and nonneoplastic disorders are more frequently associated with virilization during pregnancy than Sertoli­Leydig cell tumors. Tumors with functioning, proliferative ovarian stroma such as the Krukenberg and the mucinous cystic tumors may be confused morphologically with sex cord­ stromal tumors. Other primary ovarian tumors that can cause virilization include luteinized thecomas and Leydig and lipid cell tumors. Finally, as described earlier, two non-neoplastic lesions of the ovary that develop during pregnancy and can be associated with virilization include the luteoma of pregnancy and the hyperreactio luteinalis (multiple luteinized follicle cysts). All these virilizing tumors and lesions must be considered in the differential diagnosis when confronted with virilization of the pregnant mother, so as to not make an erroneous clinical diagnosis of a sex cord­stromal tumor. With one exception, the patients in the study by Young and colleagues were initially treated by conservative surgical procedures. Two of them received chemotherapy and two received radiation therapy postoperatively. Hysterectomies and salpingo-oophorectomies were performed as second operations in 8 cases; no residual tumor was found in any of these specimens. Adjuvant therapy has not been demonstrated to improve the outcome in this group of patients and is not recommended during pregnancy. Chemotherapy for Nonepithelial Ovarian Cancer During Pregnancy A recent literature review by Azim and colleagues identified 18 cases of nonepithelial ovarian malignancies treated with systemic chemotherapy during pregnancy. Other histologies reported included 3 cases of dysgerminoma, 3 cases of immature teratoma, 1 mixed germ cell tumor, and 1 Sertoli­Leydig tumor. Postnatal chemotherapyinduced adverse events were restricted to one baby who developed minor anemia and transient respiratory distress at delivery at the 35th week of gestation. This baby had been exposed to three cycles of carboplatin plus paclitaxel for a maternal dysgerminoma and the condition resolved quickly and the authors reported normal development at 20 months of follow-up. Epithelial Ovarian Cancer in Pregnancy Very few series of malignant ovarian carcinomas in pregnancy have been published. Reported in 2002, the most recent series contains nine ovarian cancers concurrent with pregnancy from Libya and Saudi Arabia. Among these cases were included seven epithelial cancers (four serous, two mucinous, one undifferentiated), one dysgerminoma, and one granulosa cell tumor. As expected, the latter two lesions occurred in younger women, aged 18 and 21 years, respectively. All seven women with epithelial cancers were multiparous (range 3-10), which is of some interest given the epidemiologic data suggesting increasing parity to be inversely related to the risk of developing ovarian carcinoma. None of the patients with more advanced disease who went on to receive chemotherapy did so during pregnancy. Thus fully six of seven women with epithelial ovarian cancers were diagnosed with early or locally advanced disease only, which does not reflect what is typically observed in the general population. It is quite certain that antenatal care including serial physical examinations and ultrasonography contributed to these early pick-ups.

This frequently omitted portion of the examination will sometimes reveal the only evidence of recurrent disease antiviral supplements order paxlovid 200mg visa. The prognosis for the patient with recurrent or advanced cervical cancer depends on the location of the disease hiv symptoms days after infection order generic paxlovid line. Of those patients with recurrent cervical cancer fiebig stages hiv infection buy paxlovid with a visa, the most favorable for therapy after primary irradiation are those with a central recurrence hiv infection rate namibia order paxlovid online. These patients are candidates for curative radical pelvic surgery hiv infection rate in egypt purchase paxlovid 200 mg with mastercard, including pelvic exenteration. With the advent of sophisticated methods of radiation therapy, including improved methods of brachytherapy and supervoltage external irradiation therapy, patients with pure central recurrence have become a rarity. A surgical attack for isolated pulmonary recurrence should be considered, especially if the latent period has been longer than 3 years. Other patients who deserve serious consideration are those with radiation bowel injury. Over the past decade, the limits of human tolerance to radiation therapy have been reached, with treatment techniques for advanced disease that include large extended fields to the periaortic area. Many patients with advanced-stage primary lesions have been treated with large doses of pelvic radiation (6000-7000 cGy), often following intraabdominal surgery. These techniques, standard radiation therapy can lead to a small but significant number of patients with chronic radiation injury to the large or small bowel. These patients often develop cachexia, which is indistinguishable from the clinical presentation of recurrent and progressive malignancy. These patients are often quickly and superficially diagnosed as having recurrent disease, and no further investigation is initiated. Careful investigation of these patients reveals a history of postprandial crampy abdominal pain causing anorexia and weight loss. The diagnostic evaluations discussed previously reveal no conclusive evidence of persistent malignancy. In most cases, these patients can be returned to health with appropriate bowel surgery, including internal bypass procedures. In every patient suspected of recurrent malignancy, an effort should be made to confirm this suspicion by biopsy (histologic confirmation), and patients who do not have a recurrence and who have radiation bowel injury should be identified. Cases of curative therapy applied to isolated lung metastases or lower vaginal recurrences are reported but occur rarely. Surgical Therapy: Radical Hysterectomy Radical hysterectomy has been reported as therapy for patients with a small recurrent cervical carcinoma following radiation. Excessive morbidity can be limited if an omental pedicle is placed at the operative site at the end of the procedure, bringing in a new blood supply to the operative field that has undergone previous radiation therapy. Since then, extensive experience with pelvic exenteration has been accumulated, and the techniques and patient selection have steadily improved so that now, 50 years later, this procedure has attained an important role in the treatment of gynecologic malignancies for a selected group of patients. It is now accepted as a respectable procedure that can offer life to selected patients when no other possibility of cure exists. Most important, however, is that patients who survive this procedure can be rehabilitated to a useful and healthful existence. Although pelvic exenteration has been used for various pelvic malignancies, its greatest and most important role is in the treatment of advanced or recurrent carcinoma of the cervix. The urinary stream is diverted into an ileal or sigmoid conduit or a continent pouch. Cogent objections have been raised regarding these limited operations, especially in patients with carcinoma of the cervix recurrent after irradiation, because of the increased risk of an incomplete resection. In addition, those patients in whom the bladder or rectum is preserved often have multiple complications and malfunctioning of the preserved organ. Consequently, some surgeons have completely abandoned subtotal exenterations, and most oncologists use them very selectively. One of the greatest technical advances in the evolution of pelvic exenteration is the intestinal conduit for diversion of the urinary stream. Originally, Brunschwig transplanted the ureters into the left colon just proximal to the colostomy, thus creating the so-called wet colostomy. The complication rate from this procedure, especially electrolyte imbalance and severe urinary tract infections, was unacceptable. The incidence of both postoperative pyelonephritis and hypochloremic acidosis has been greatly reduced. Another significant advancement in surgical technique of these patients is the use of the intestinal stapling device. Whereas a permanent colostomy was a standard part of the exenterative procedure, today, it is rare. In many, if not most, cases, reanastomosis with the end-to-end anastomosis stapler can be performed and the fecal stream continues through the anus. Patient Selection Only a few patients with recurrent cancer of the cervix are suitable for this operation (Table 3-26). The triad of unilateral leg edema, sciatic pain, and ureteral obstruction is pathognomonic of recurrent and unresectable disease in the pelvis. Weight loss, cough, anemia, and other aberrations suggestive of advanced disease are not sufficient justification by themselves to discontinue efforts toward surgical management. Some patients are unsuitable because of psychological reasons, and a number of women who are otherwise candidates Low colonic anastomosis Shaded tissue within the dashed outline is permanently removed. Unshaded tissue within the dashed outline is first removed and then reconstructed. Any suspected disease outside the pelvis noted on any of the diagnostic studies should prompt an attempt at confirmation using a fine needle biopsy technique. The lymph nodes surrounding the lower aorta are the first to be sampled if the exploration of the abdomen has revealed no evidence of disease. If the lower aortic area findings are negative, a bilateral pelvic lymphadenectomy is performed. Laparotomy with careful search for peritoneal, liver, and other visceral implants 2 3. Biopsy of central recurrence in uterus or vagina Morbidity and Mortality Most of the morbidity and mortality directly related to exenteration occur within the first 18 months following the procedure. These include cardiopulmonary catastrophes such as pulmonary embolism, pulmonary edema, myocardial infarction, and cerebrovascular accidents. The length of these surgical procedures and the magnitude of blood loss definitely increase the incidence of cardiovascular complications. This category of complications usually occurs within the first week after the procedure. This sepsis usually originates in the pelvic cavity with occurrence of a pelvic abscess or, more commonly, diffuse pelvic cellulitis. One of the most serious postoperative complications of exenteration is small-bowel obstruction related to the denuded pelvic floor. When small-bowel obstruction does occur, it is appropriately treated with conservative therapy. Both conditions predispose to the development of small-bowel fistulas, which always require reoperation and frequently are fatal. In general, complications are more common in patients who have recurrence after radiation therapy. Irradiated tissue is less likely to produce good wound healing, and the formation of granulation tissue is severely retarded. The long-term morbidity from exenteration is predominantly related to urinary diversion. Once the period of susceptibility to sepsis has passed, urinary obstruction and infection become the major non-neoplastic lifethreatening complications. A mild degree of obstruction is frequently retained following construction of an ileal conduit, but progressive hydronephrosis will require correction to salvage renal function. Reported survival rates depend greatly on the circumstances of patient selection for exenteration. Cumulative survival rates are always improved when no patient is exenterated who has a positive pelvic node following pelvic irradiation. In general, however, both morbidity and mortality and the 5-year survival rate have improved steadily over the past two decades. In 2009, 60 years following the first description of pelvic exenteration, Marnitz and colleagues surveyed and compared practice patterns in the United States and Germany. The number of exenterations performed in the twenty-first century was comparable in both countries, with centrally recurrent cervical cancer or persistent tumor after chemoradiation being the main indication. In Germany, interdisciplinarity with general surgeons, urologists, plastic surgeons, and radiation oncologists is more common. In 2010 Spahn and colleagues reported the results of 37 anterior pelvic exenterations and 6 total pelvic exenterations performed at the University of Wurzburg in Germany. A continent urinary diversion was constructed in 16 and an ileal conduit was constructed in 27. Continent urinary diversion was not associated with higher complication rates than ileal conduit formation. For vaginal reconstruction, vascularized muscle flaps are preferred to fill the empty pelvis, and developments in bioengineering tissue are likely to have applications in neovaginal creation. De la Garza and colleagues reported the successful performance of a total pelvic exenteration with a split-thickness skin graft neovagina, continent orthotopic neobladder, and rectal anastomosis, resulting in no external ostomies and adequate sexual function. Radiation With recurrent disease outside the initial treatment field, irradiation is frequently successful in providing local control and symptomatic relief. With time, the omental "carpet" will descend into the pelvis and the "carpet" will adhere to the pelvic floor. A dose of 3000 cGy delivered over 2 to 3 weeks is often sufficient to relieve pain from vertebral column or long-bone metastases. Although the combination therapy is not new, these authors surgically remove the recurrence more radically than previously reported. Implantation of guide tubes, which exit from the skin for brachytherapy, is done after resection of the tumor. Reirradiation of pelvic recurrences of cervical cancer occurring within the previously treated field is a subject of some controversy. The results following reirradiation of patients with recurrent cervical malignancy have varied considerably. At the Roswell Park Memorial Institute, Murphy and Schmitz adopted the policy of reirradiating patients with recurrence, delivering a full or almost full course for a second time. Others have shown that the results of reirradiation depend on many factors, including the site of recurrence, initial clinical stage, and initial dose of radiation therapy. Careful perusal of these reports suggests that most patients who benefited from reirradiation were those who received less than optimal radiation during initial therapy. This set of circumstances has become rare in recent times, when more sophisticated radiotherapy is being delivered in many areas of the United States. Therefore, reirradiation for recurrent disease is usually not a worthwhile consideration. The potential for necrosis and fistula formation with even moderate doses of reirradiation in the pelvis by external or interstitial sources can give very unfavorable results. In a study from Holland, 271 patients were treated with radical hysterectomy and 27 recurred with 14 limited to the pelvis. In the 4 patients with isolated pelvic recurrence, only 1 died of disease, whereas all of the other patients with recurrences died of disease. Chemotherapy the management of disseminated cervical cancer has improved with the development of modern chemotherapy. Because concurrent platinum-based chemoradiation has become the standard of care for locally advanced disease, many recurrent tumors may therefore be platinum resistant. The next two trials evaluated the addition of ifosfamide, bleomycin, and mitolactol to cisplatin-based therapies. The first is a chemotherapy question and concerns whether nonplatinum agents would have greater activity in the recurrent setting given the increased usage of platinum-based chemoradiation initially for locally advanced cancers. Tiersten and colleagues reported on their experience with the nonplatinum doublet topotecan plus paclitaxel. The laboratory work by Bahadori and colleagues demonstrating synergy between paclitaxel and microtubule-inhibiting agents. Tumor angiogenesis as measured by microvessel quantification has been shown to be a prognostic factor in cervical cancer. We are seeing increasing evidence that therapy for metastatic cervical carcinoma does not need to be solely palliative. Additionally, in 2009 Takano and colleagues reported complete remissions in two patients with metastatic and recurrent cervical cancer. Before recurrence, one patient had received chemoradiation for locally advanced disease and the other had been treated with adjuvant pelvic radiation following hysterectomy. Targeted Therapies Angiogenesis Inhibitors As discussed earlier, biologic therapy in the form of angiogenesis inhibitors may be useful in retarding tumor growth and progression and even eliminating small-volume residual disease. Evidence that angiogenesis plays an important role in locally advanced cervical cancer has accumulated in recent years. To determine whether the addition of bevacizumab to chemotherapy improves overall survival. To determine whether the nonplatinum chemotherapy doublet consisting of topotecan plus paclitaxel improves overall survival in comparison to the regimen involving cisplatin plus paclitaxel. To estimate and compare the progression-free survival of patients treated by the regimens investigated on this study. To estimate and compare the proportion of patients with tumor responses by the regimens investigated on this study. To isolate circulating tumor cells recovered from blood and determine their association to measures of clinical outcome.

These methods are based on correlations of Cr Cl with age hiv infection mosquito bite order paxlovid without prescription, body weight hiv infection rate female to male 200mg paxlovid for sale, serum creatinine hiv infection impairs what buy 200mg paxlovid with mastercard, and creatinine metabolism antiviral natural buy discount paxlovid online. Jelliffe Method the Jelliffe method was used originally as a simple estimate of Cr Cl using serum creatinine hiv infection stages best 200 mg paxlovid, making minor adjustments in the calculation for female patients. The current Jelliffe formula takes into consideration age and renal function, and is as follows: Cr Cl (mL /min) = 1. This method is similar to the Jelliffe calculation and is as follows: Cr Cl = (140 - age) × (lean body weight in kg)/(serum creatinine) × 72. Calvert Formula the use of the Cr Cl has also been incorporated into the so-called Calvert formula. Many clinicians favor limiting body surface area to 2 mg/m2 in calculation of dosage. The adverse effects criteria table used by the Gynecologic Oncology Group is included as Appendix B. These adjustments reduce the likelihood of overly high plasma drug concentrations and the attendant risk of serious renal toxicity. Alkylating agents now used in gynecologic oncology are as follows: · · · · · · · · · Carboplatin Cisplatin Oxaliplatin Cyclophosphamide Chlorambucil Melphalan Triethylenethiophosphoramide Ifosfamide Altretamine (hexmethylmelamine) breaks. These drugs are as follows: · Vinca alkaloids: · Vinblastine · Vincristine · Vinorelbine · Taxanes: · Paclitaxel · Protein-bound paclitaxel · Docetaxel · Epipodophyllotoxins: · Etoposide · Camptothecin analogs: · Topotecan · Irinotecan · Epothilones: · Ixabepilone Antimetabolites Antimetabolites act by inhibiting essential metabolic processes that are required for synthesis of purines, pyrimidines, and nucleic acids. The currently used drugs in this category are as follows: · · · · · · 5-fluorouracil Methotrexate Cytarabine Capecitabine Gemcitabine Pemetrexed Hormonal Agents these agents are often utilized in the treatment of endometrial, breast, and ovarian cancers and are classified in two broad categories: antiestrogens and progestational agents. Megestrol acetate may both downregulate estrogen-responsive genes and reduce the number of available cell surface estrogen receptors. Several cytotoxic antibiotics have come into use for chemotherapy of certain neoplasms. Those used in gynecologic oncology are as follows: · Dactinomycin (actinomycin D) · Bleomycin · Doxorubicin and liposomal doxorubicin hydrochloride · Mitomycin C · Mitoxantrone Targeted Therapies/Immunotherapy To date, traditional chemotherapy has predominantly focused on killing rapidly dividing cells. Targeted therapies have attempted to focus anticancer treatment on particular pathways and mechanisms that cause cancer to both increase efficacy and decrease toxicity in comparison with traditional chemotherapies. These therapies may aim to affect pathways for angiogenesis, cell cycle, and apoptosis in tumor cells. As part of anticancer therapy, monoclonal antibodies have been used in two fashions. First, Agents Derived from Plants Several chemotherapeutic agents have been developed from plants. Second, monoclonal antibodies have been conjugated to a strongly radioactive atom, such as iodine-131, to aid in killing the target. Other targeted therapies focus on the internal components and function of the cancer cell, using small molecules to disrupt the function of the cells, triggering apoptosis. There are several types of targeted therapy that focus on the inner parts of the cells. Collectively, these therapies cannot currently be considered replacement for traditional cytotoxics but may be best used in combination with chemotherapeutic agents. The incidence of severe side effects of chemotherapeutic agents is greatly influenced by states such as severe disability, advancing age, poor nutrition, or direct organ involvement by primary or metastatic lesions. The physician must monitor these patients with extreme care, and appropriate dose modifications must be made (Table 17-8). Hematologic Toxicity Hematologic toxicity is the most frequently seen side effect. Acute granulocytopenia occurs 6-12 days after the administration of most myelosuppressive chemotherapeutic agents. The megakarocyte series is affected later, such that platelet suppression usually occurs 4 or 5 days after granulocytopenia and recovers several days after the white blood cell count. Mitomycin C and nitrosourea are particularly unique in their ability to produce delayed bone marrow suppression. Myelosuppression with these two drugs commonly occurs within 28-42 days, with recovery 40-60 days after treatment. Most clinicians consider patients with absolute granulocyte counts less than 500/mm3 for 5 days or longer to be at a higher risk for sepsis. The practice of utilizing prophylactic broad-spectrum antibiotics in febrile granulocytopenic cancer patients has significantly decreased the incidence of life-threatening infections in this group of patients. Granulocytopenic patients should have their temperature checked every 4 hours, and they should be examined frequently for evidence of infection. Thrombocytopenic patients with platelet counts less than 20,000/mm3 are at increased risk for spontaneous hemorrhage, particularly from the gastrointestinal tract. Routine platelet transfusions for platelets under 10-20,000/mm3 have been utilized by some clinicians. Usually, the mechanism of toxicity is similar to the one producing the desired cytotoxic effect. Even organs with limited cell proliferation can be damaged by chemotherapeutic agents, especially if the agents are utilized at high doses. Chemotherapeutic agents must be used at doses that produce some degree of toxicity to normal tissue in 17. Repeat transfusions of platelets at 2to 3-day intervals may be necessary in patients with severe thrombocytopenia. Patients with active peptic ulcer disease and patients needing surgical procedures need to be transfused with counts lower than 50,000/ mm3. Rapid advances in unraveling the molecular biology and biochemistry of these glycoprotein hormones that regulate hematopoiesis have led to their routine clinical use. Since their emergence in 1989, their use has allowed amelioration of therapyrelated myelosuppression, modulation of disease-related myelosuppression, and enhanced host defense to infection. The biologic activities of these proteins are complex and multifunctional, stimulating potent changes in the growth, differentiation, distribution, and functional status of mature cells and their precursors (Table 17-9). Since then, numerous studies have shown that subcutaneous administration once or twice a day is even more myelostimulatory than 2- to 4-hour intravenous infusions. Treatment should begin at least 24 hours after completion of chemotherapy, and should continue daily until the absolute neutrophil count exceeds 10,000/mm3. Subsequent chemotherapy should not begin until at least 48 hours have elapsed since the last dose. A subcutaneous injection is recommended at least 24 hours after the completion of chemotherapy infusion, and should not be given within 14 days of any subsequent chemotherapy. In 1985 two independent groups cloned the gene responsible for this growth factor. Apparently, the site of production in the fetus is the liver, and in the last third of the gestational period the responsibility is gradually transferred to the kidney. Erythropoietin stimulates the division and differentiation of committed erythroid progenitors in the bone marrow. It is produced by mammalian cells into which the human Epo gene has been introduced. Most patients on chemotherapy develop anemia at some point during the course of their illness. The hemoglobin concentration of these patients usually ranges from 7 to 12 g/dL, and the hematocrit is somewhere between 25% and 38%. However, there appears to be a large blunting of response to Epo in patients who have undergone chemotherapy. Epoetin reduces the transfusion requirement in anemic patients and may enhance overall quality of life, and administration is indicated when hemoglobin levels have decreased below 10 mg/dL during chemotherapy treatment, or when a significant chance for blood transfusion exists. Epoetin injected at a dose of 150 U/kg subcutaneously three times a week for 12 weeks has been used by many clinicians. Others utilize a daily dose of 60 U/kg, progressing to a maximum dose of 90 U/kg per day. Another commonly used approach is to inject 40,000 U/week, with escalation to 60,000 U for nonresponders. Adverse effects are uncommon but include worsening hypertension in patients with end-stage renal disease. Food and Drug Administration issued a black box warning regarding the use of both epoetin alfa and darbepoetin alfa. Research also indicates that the erythropoietin receptor is expressed in several cancer cell lines, raising the concern of possible stimulation of tumor cell growth by these drugs. Epoetin has also been implicated in possible thromboembolic complications, possibly related to elevated hemoglobin levels. Physicians must complete a 15-minute online education course and document informed consent from the patient prior to administration. The usual dose is 50 µg/kg, which is given once daily subcutaneously as a single injection in the abdomen, thigh, or hip. Treatment should begin 6-24 hours after completion of chemotherapy and continued until the nadir platelet count is 50,000 cells/µL. Mucositis may be caused by direct effects on the rapidly dividing epithelial mucosa. Concomitant granulocytopenia allows the injured mucosa to become infected and serve as a portal of entry for bacteria and fungi. Candidiasis is often seen and is difficult to distinguish from stomatitis secondary to chemotherapy; antifungal agents have been very effective in treating this condition. Symptoms of this condition are watery or bloody diarrhea, abdominal pain, nausea, vomiting, and fever. Most necrotizing enterocolitis is caused by anaerobic bacteria such as Clostridium difficile. Although the exact mechanisms are not clearly defined, most agents appear to stimulate the chemoreceptor trigger zone in the area postrema of the brain to secrete neurotransmitters such as dopamine, serotonin, and histamine. These neurotransmitters may activate the neighboring vomiting center to induce nausea and emesis. Direct stimulation of serotonin receptors in the gastrointestinal tract, direct cerebral action, and psychogenic effects may also play a role. Different patterns of emesis include acute emesis (within 24 hours of chemotherapy infusion), delayed emesis (typically beginning 16-24 hours after chemotherapy but persisting up to 72-96 h), and anticipatory emesis. Choice of agents should be governed by knowledge of the emetogenic potential of the chemotherapies administered (Table 17-11). A premedication regimen should consist of a combination of antiemetics given 30 minutes prior to chemotherapy infusion. Moderately emetogenic chemotherapies include lower doses of cisplatin (<50 mg/m2) and cyclophosphamide (750-1500 mg/m2) and carboplatin, doxorubicin, methotrexate (>1000 mg/m2), ifosfamide, and high-dose 5-fluorouracil. Mildly emetogenic chemotherapies include methotrexate, paclitaxel, docetaxel, liposomal doxorubicin, gemcitabine, bleomycin, and etoposide. Management includes removal of the intravenous line and local infiltration of the area with corticosteroidsand ice pack therapy four or five times a day for 3 days. Palmar­plantar erthrodysesthesia, or hand and foot syndrome, may be a dose-limiting toxicity of liposomal doxorubicin and is characterized by painful edema and erythema. Unlike reactions to taxanes, which typically occur within minutes of starting the initial dose, reactions to platinum agents typically do not manifest until several cycles have already been administered. In one series, a median of eight platinum courses were administered before hypersensitivity occurred. Routine premedication for hypersensitivity is not recommended, and patients who experience mild reactions may respond well to the addition of appropriate premedications. Patients with severe reactions may attempt systematic desensitization if indicated, although success is variable. Mild elevations in transaminase, alkaline phosphatase, and bilirubin are seen with many agents, but rarely is the condition severe. Psoriasis and drug-induced hepatitis can affect the amount of the chemotherapeutic agent given, as can preexisting liver disease or exposure to other hepatic toxins. Hypersensitivity Many chemotherapeutic agents may be associated with hypersensitivity reactions, although only a few agents elicit these responses in more than 5% of patients. Of the agents commonly used in gynecologic oncology, the taxanes and platinum compounds are the most likely culprits, although occasional reactions may also be seen with bleomycin, doxorubicin, etoposide, cyclophosphamide, ifosfamide, and methotrexate. In phase I trials, the incidence of severe hypersensitivity to paclitaxel was approximately 30%; however, with adequate prophylaxis (Table 17-12) the incidence is now less than 10%. With appropriate premedication, hypersensitivity to docetaxel has been reduced to 2% to 3%. The occurrence of hypersensitivity does not preclude further treatment with the drug. If additional diphenhydramine or corticosteroids do not allow the infusion to be completed after a delay, patients may undergo successful systematic desensitization. Pulmonary Toxicity Interstitial pneumonitis with pulmonary fibrosis is seen with certain chemotherapeutic agents. Treatment of patients with druginduced interstitial pneumonitis involves discontinuation of the cytotoxic agent and supportive care. The risk increases dramatically when the cumulative dose exceeds 500 mg/m2 of ideal body surface area. In recent years, this limit has rarely been exceeded; thus cardiomyopathy has diminished greatly in incidence. Acute arrhythmias may often be seen, but these disappear with a few days of supportive care. On rare occasions, cyclophosphamide has been reported to produce cardiotoxicity, particularly when it is used in massive doses. Proximal and distal tubule damage leads to electrolyte wasting and increase in serum creatinine with concomitant decrease in Cr Cl. If the first cycle of treatment is well tolerated, subsequent cycles may be premedicated using oral doses. Antibiotic therapy with aminoglycosides potentiates the nephrotoxicity of drugs such as cisplatin and should be avoided if possible. In women older than 30 years of age, most chemotherapeutic regimens are associated with a high incidence of premature ovarian failure.

There are two primary mechanisms for the growth of new blood vessels in both the normal and tumor microenvironment primary infection symptoms of hiv order 200mg paxlovid fast delivery. Sprouting hiv infection rates in poland buy cheapest paxlovid, the dominant means of vessel formation antiviral lip balm buy paxlovid 200 mg low cost, is the branching of a new vessel from 18 hiv transmission statistics united states discount paxlovid 200mg with visa. In ovarian cancer hiv infection flu symptoms buy paxlovid without prescription, bevacizumab has been evaluated both as a single agent and in combination therapy for primary and recurrent disease. The risk of bowel perforation appeared to be higher in those patients with a higher median number of prior treatments and in whom impending bowel obstruction was suspected. Further studies are ongoing to elucidate a clear list of risk factors for perforation in the setting of bevacizumab therapy. This combination has also been evaluated retrospectively at several institutions with similar encouraging results (objective response rate 44% to 53. However, this trial was stopped early secondary to lack of clear benefit of the combination over singleagent bevacizumab and a higher than expected rate of bowel perforation (15%). Micha and colleagues noted an objective response rate of 80% among 21 patients with acceptable toxicity. An additional study of this regimen in 62 women after debulking surgery found a comparable response rate of 76% and a progression-free survival rate of 58% at 36 months. This study included 1 year of maintenance bevacizumab (15 mg/kg every 21 days), which resulted in mild toxicity over a median of 17 maintenance bevacizumab cycles. It is interesting that there was no progression-free survival benefit in the patients who only received adjuvant bevacizumab compared to standard therapy alone. In the arm receiving paclitaxel, carboplatin, and bevacizumab followed by bevacizumab maintenance, the progression-free survival was improved by 1. This trial aims to evaluate progressionfree survival and potential gastrointestinal toxicity of this combination. Each arm undergoes an additional randomization for possible addition of bevacizumab to the regimen. A retrospective review of eight patients with recurrent granulosa cell tumors demonstrated a partial response rate of 38% and stable disease rate of 25%. These tumors are notoriously chemoresistant, and this study has encouraged the development of 18. A retrospective review of 11 patients with uterine cancer treated with bevacizumab combination therapy revealed two partial responses and three patients with stable disease. Multiple trials are currently under way to evaluate bevacizumab alone and in combination for the treatment of uterine cancer. Of note, the combination of bevacizumab and radiation therapy is also under evaluation in this disease site. There are several trials with bevacizumab in cervical cancer actively accruing in the upfront and recurrent settings. A response rate of 11% was reported with five partial responses and no mention of stable disease. Columbo and colleagues treated 12 patients with aflibercept (4 mg/kg) every 2 weeks and found successful prolongation in time to repeat paracentesis with minimal adverse advents. Recurrent ovarian, primary peritoneal, fallopian tube cancer treatment-free interval 6 months Primary treatment phase Carboplatin Paclitaxel Placebo Carboplatin Paclitaxel Cediranib Carboplatin Paclitaxel Cediranib Maintenance phase Placebo Placebo Cediranib ovarian cancer. As expected, the most frequent afliberceptassociated toxicity was hypertension (11% grade 1 or 2). A phase I trial in 12 patients with advanced solid malignancy demonstrated a clinical benefit in 9 patients (2 partial responses, 7 with stable disease). In a study of 46 patients with recurrent ovarian cancer, the clinical benefit rate of single-agent cediranib was 30%. Eight patients achieved partial response and 6 patients had stable disease, and median progression-free survival for the group was 5. Hirte and colleagues reported a response rate of 41% in platinumsensitive and 29% in platinum-resistant ovarian malignancy. Toxicities in both studies included diarrhea, hypertension, mucositis, fatigue, and anorexia. Pazopanib 800 mg daily Lapatinib 1000 mg daily Pazopanib and lapatinib Pazopanib 400 mg daily and lapatinib 1000 mg daily Pazopanib 800 mg daily and lapatinib 1500 mg daily cancer demonstrated a 70% clinical benefit with partial response in 2 patients and stable disease in 10 patients. Common side effects were hand and foot reaction, fatigue, hypertension, and mucositis. Although they achieved no objective responses, 16 patients achieved stable disease with a median duration of 4. Ongoing ovarian cancer studies of pazopanib include combination with liposomal doxorubicin in the recurrent setting and in combination with paclitaxel/carboplatin in the upfront setting. Activity against ovarian cancer is being actively explored and has been promising in a front-line phase I trial in advanced disease in combination with paclitaxel and carboplatin. This compound has demonstrated acceptable toxicity and activity when given alone or in combination, in multiple solid tumors, including hepatocellular carcinoma refractory to other antiangiogenic therapies. A phase I trial of this agent in patients with gynecologic malignancies revealed a promising response rate, with five of seven patients with measurable disease demonstrating response and two achieving stable disease. This agent is currently under investigation in a randomized control trial combined with standard paclitaxel and carboplatin in previously untreated primary ovarian cancer patients. The disturbance of existing vessels leads to ischemia, hemorrhagic necrosis, and ultimately cellular death. Of note, these agents are able to selectively target tumor blood vessels by taking advantage of the differences between normal and tumor endothelial cells. Two major types of vascular disrupting agents exist: small molecule­ based and ligand-based. The majority of vascular disrupting agents under evaluation in gynecologic cancers target small molecules. Gabra and colleagues evaluated this drug in combination with paclitaxel and carboplatin for the treatment of recurrent ovarian cancer. The arm that received vadimezan conferred significant improvement in response rate when compared to the control arm (64% vs 49%) without additional adverse effects. This agent has been evaluated primarily for the treatment of platinum-resistant ovarian cancer. Ombrabulin is a combrestatin derivative that has shown excellent efficacy in preclinical ovarian cancer models. Other Anti-Angiogenic Agents Thalidomide Thalidomide is a legacy agent that has found recent renewed interest as an anti-angiogenic agent. Thalidomide (200 mg daily) added 4 months to overall survival when added to topotecan (1. In this study, there was essentially no difference in progression-free survival, with thalidomide achieving 3. Common toxicities of thalidomide include hematologic, gastrointestinal, and cardiovascular complications. Thalidomide is currently under evaluation in ovarian cancer as a possible consolidation agent and in combination with carboplatin in the recurrent setting. Lenalidomide (Revlimid) is a thalidomide derivative currently under analysis in combination with traditional cytotoxic agents for recurrent ovarian cancer. As described in Chapter 19, the aforementioned mutations are commonly found in endometrial cancer and less frequently in the other gynecologic malignancies. Furthermore, this pathway is thought to be targeted more frequently in cancer than any other pathway aside from p53. Currently, the drugs targeting this pathway consist primarily of small-molecule inhibitors of key pathway components. The inhibition of only one member of the pathway may not be sufficient to affect tumor growth given the significant pathway cross-talk and feedback loops. Twenty-five percent of 19 evaluable patients had a partial response and an additional 63% achieved stable disease. Temkin and colleagues reported on a phase I trial of temsirolimus combined with topotecan to treat a variety of advanced and recurrent gynecologic malignancies. The drug combination was well tolerated in patients without a history of radiotherapy and achieved stable disease in 9 of 11 patients at 8 weeks. Trials incorporating temsirolimus have shown manageable toxicities including hypertriglyceridemia, hyperglycemia, electrolyte abnormalities, and rash. Ongoing studies of this drug in endometrial cancer include combination regimens of temsirolimus and a variety of cytotoxic and hormone therapies. There are three arms in this trial, including temsirolimus in combination with paclitaxel and carboplatin; compared to bevacizumab, paclitaxel, carboplatin; and ixabepilone, paclitaxel, carboplatin. Other studies combining temsirolimus with bevacizumab in ovarian cancer and temsirolimus as a single-agent therapy in advanced or recurrent cervical cancer are ongoing. Given these results, current studies of this drug are in combination with other targeted agents, traditional cytotoxic chemotherapy, and hormones. Overall, 150 patients (114 evaluable) were enrolled; 64 to ridaforolimus, 53 to hormonal therapy, and 13 to chemotherapy. The response rates in each arm were similar (8% vs 4% for ridaforolimus and control, respectively). A trial combining this drug with docetaxel in recurrent ovarian cancer is currently ongoing. This included 37% of ovarian and 44% of endometrial cancer patients with stable disease. Most common toxicities were fatigue, elevated liver transaminases, and gastrointestinal disorders. A phase I dose escalation study in patients with solid tumors has been completed to identify tolerance of the compound at 60 mg orally every other day. As already noted, given the extensive cross-talk and feedback loops involved in this pathway, the inhibition of two major nodes in the pathway is rational and will likely lead to improved outcomes. Although the receptors are activated through a traditional tyrosine kinase receptor mechanism, they also require the union between two identical receptors (homodimerization) or two different receptors within the same family (heterodimerization) for downstream activation. Thus targeting this pathway has been an area of significant research for the treatment of gynecologic malignancies. Thus the blockage of kinase activity with antibodies or small molecules may not be sufficient to make a significant impact on tumorigenesis. This agent has been evaluated extensively in ovarian cancer with unsatisfactory results. This suggests that the use of mutation status to guide targeted therapies may provide better response rates. Nineteen percent of platinum-resistant and 62% of platinum-sensitive patients had response to this combination therapy. Overall survival was also acceptable, reaching 17 months for the resistant group and 26 months for the sensitive group. However, there appeared to be more hematologic toxicity when compared to the standard regimen. The combination of gefitinib (500 mg daily) with tamoxifen (40 mg daily) in recurrent ovarian cancer required dose reduction secondary to diarrhea in 10 of 56 patients and resulted in no objective responses. The only published trial of gefitinib (500 mg daily) in cervical cancer reported minimal activity. Of 28 evaluable patients, there were no objective responses and 20% achieved stable disease for a median duration of 112 days. Additional trials of gefitinib monotherapy in recurrent cervical, endometrial, and ovarian cancer are ongoing. Furthermore, gefitinib is under evaluation for treatment of recurrent ovarian cancer in combination with topotecan and anastrazole. In the setting of recurrent ovarian cancer, erlotinib has been primarily evaluated in combination with other therapies, although a solo trial is ongoing. As noted previously, a trial of erlotinib with bevacizumab (15 mg/kg) was terminated early secondary to a high level of bowel perforation. The use of erlotinib as a single agent in chemotherapy-naïve endometrial cancer was well tolerated and 4 of 32 patients had an objective response. Schilder and colleagues reported disappointing results of erlotinib as a single agent in cervical cancer, with only 1 of 25 patients achieving objective response and 4 with stable disease. The combination of erlotinib with cisplatin (40 mg/m2 weekly) with radiotherapy in locally advanced cervical cancer was found to be feasible, with acceptable toxicity and a complete response rate of 91%. Further studies of this drug as a single agent in cervical cancer and as a consolidation therapy in ovarian cancer are ongoing. As a single agent in 25 patients, cetuximab achieved only 1 partial response and 9 patients with stable disease. Cetuximab and cisplatin (30 mg/ m2) for recurrent cervical cancer was better tolerated but did not show any additional benefit compared to historical rates of cisplatin alone. Although this drug has found great success in the treatment of Her-2/neu­positive breast cancer, its use in gynecologic oncology has been limited. Of 30 patients, 12 had stable disease, and the trial was closed early secondary to poor accrual. In a trial of two dosing regimens of pertuzumab (840 mg loading with 420 mg every 21 days vs 1050 mg every 21 days), five patients achieved partial response and eight patients had stable disease. A large randomized trial comparing gemcitabine (800 mg/m2) alone to gemcitabine with pertuzumab (420 mg every 21 days) found that the addition of pertuzumab resulted in improved response rates (4. Further studies of pertuzumab for the treatment of recurrent ovarian cancer are accruing. Although no clinical responses were observed, 21% of patients achieved stable disease for more than 3 months with acceptable toxicity. These results are especially encouraging given the high number of median prior therapies in this group of patients. Other combinations with lapatinib including carboplatin and topotecan have not been as successful and have demonstrated unacceptable toxicity. The use of lapatinib in combination with pazopanib in cervical cancer was discussed earlier in the chapter.

Purchase paxlovid amex. Atlanta HIV/AIDS Epidemic worse than third world African countries!.

References